ArticleClinical and molecular hepatology2024
Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK.
Article in Clinical and molecular hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Association between residential greenness and the risk of inflammatory bowel disease in patients with COVID-19: A Korean nationwide cohort study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study.Clinical and molecular hepatology · 2026Article
- Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks.Clinical and molecular hepatology · 2026Article
- Clinical features and inflammatory signatures of patients with persistent gastrointestinal long COVID two years after severe SARS-CoV-2 infection.Scientific reports · 2026Article
- Live zoster vaccination and hepatobiliary risk reduction: a nationwide South Korean study.The Korean journal of internal medicine · 2025Article
- Expression of SARS-CoV-2 entry receptor ACE2 in human brain and its association with Alzheimer's disease and COVID-19.Molecular psychiatry · 2025Review
- Post-COVID-19 Pandemic Sequelae in Liver Diseases.Life (Basel, Switzerland) · 2025Review
- Review
- Artificial intelligence models predicting abnormal uterine bleeding after COVID-19 vaccination.Scientific reports · 2025Article
- Reply to correspondence on "Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK".Clinical and molecular hepatology · 2025Article
- Correspondence to editorial on "Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: a multinational population-based cohort study from South Korea, Japan, and the UK".Clinical and molecular hepatology · 2025Article
- Understanding the impact on digestive disease in the post-COVID-19 condition: Editorial on "Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK".Clinical and molecular hepatology · 2025Article
- Global Estimates of Vaccine-Associated Hepatic Autoimmune Disorders and Their Related Vaccines, 1968-2024: An International Analysis of the WHO Pharmacovigilance Database.International archives of allergy and immunology · 2025Article
- Sex-Specific Trends in the Prevalence of Osteoarthritis and Rheumatoid Arthritis From 2005 to 2021 in South Korea: Nationwide Cross-Sectional Study.JMIR public health and surveillance · 2024Article
- Impact of preexisting digestive problems on the gastrointestinal symptoms of patients with omicron variant of SARS-CoV-2 infection.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND/
aimsConsidering emerging evidence on long COVID, comprehensive analyses of the post-acute complications of SARS-CoV-2 infection in the gastrointestinal and hepatobiliary systems are needed. We aimed to investigate the impact of COVID-19 on the long-term risk of gastrointestinal and hepatobiliary diseases and other digestive abnormalities.
methodsWe used three large-scale population-based cohorts: the Korean cohort (discovery cohort), the Japanese cohort (validation cohort-A), and the UK Biobank (validation cohort-B). A total of 10,027,506 Korean, 12,218,680 Japanese, and 468,617 UK patients aged ≥20 years who had SARS-CoV-2 infection between 2020 and 2021 were matched to non-infected controls. Seventeen gastrointestinal and eight hepatobiliary outcomes as well as nine other digestive abnormalities following SARS-CoV-2 infection were identified and compared with controls.
resultsThe discovery cohort revealed heightened risks of gastrointestinal diseases (HR 1.15; 95% CI 1.08-1.22), hepatobiliary diseases (HR 1.30; 95% CI 1.09-1.55), and other digestive abnormalities (HR 1.05; 95% CI 1.01-1.10) beyond the first 30 days of infection, after exposure-driven propensity score-matching. The risk was pronounced according to the COVID-19 severity. The SARS-CoV-2 vaccination was found to lower the risk of gastrointestinal diseases but did not affect hepatobiliary diseases and other digestive disorders. The results derived from validation cohorts were consistent. The risk profile was most pronounced during the initial 3 months; however, it persisted for >6 months in validation cohorts, but not in the discovery cohort.
conclusionThe incidence of gastrointestinal disease, hepatobiliary disease, and other digestive abnormalities increased in patients with SARS-CoV-2 infection during the post-acute phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.